Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Gut

• Publication date

  2012-08-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gutjnl-2011-301430PMID 22859496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic hepatitis B : an update

  2010cited by this paper
• Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

  2010cited by this paper
• Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b

  2009cited by this paper
• 924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP

  2009cited by this paper
• EASL Clinical Practice Guidelines: management of chronic hepatitis B.

  2009cited by this paper
• Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.

  2009cited by this paper
• Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

  2009cited by this paper
• Chronic hepatitis B: Update 2009

  2009cited by this paper
• Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.

  2009cited by this paper
• Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B

  2009cited by this paper
• Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.

  2009cited by this paper
• Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

  2008cited by this paper
• A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B

  2007cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

  2006cited by this paper
• Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.

  2005cited by this paper
• Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

  2004influential reference
• Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

  2004cited by this paper
• Long‐Term suppression of hepatitis B e antigen‐negative chronic hepatitis B by 24‐month interferon therapy

  2003cited by this paper
• World‐wide epidemiology of HBeAg‐negative chronic hepatitis B and associated precore and core promoter variants

  2002cited by this paper
• Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

  2001cited by this paper
• Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

  2001cited by this paper
• Long term response to therapy of chronic anti-HBe–positive Hepatitis B is poor independent of type and schedule of interferon

  1999cited by this paper
• A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

  1997cited by this paper

• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers

  2025cites this paper
• Mechanistic modeling to understand variability in responses to chronic Hepatitis B treatment

  2024cites this paper
• Systematic review with network meta-analysis: sustained hepatitis B surface antigen clearance after pegylated interferon cessation

  2024cites this paper
• How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review

  2022cites this paper
• KASL clinical practice guidelines for management of chronic hepatitis B

  2022influential citation
• The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B

  2022cites this paper
• Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B

  2022cites this paper
• Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B.

  2021cites this paper
• Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis

  2021cites this paper
• Abstract

  2021cites this paper
• Management of Patients With Chronic Hepatitis B (Hepadnaviridae) and Chronic Hepatitis D Infection (Deltavirus)

  2021cites this paper
• Chronic Hepatitis B Virus Infection: Interferon Therapy and Long-Term Outcomes

  2021cites this paper
• Leitlinienreport zur aktualisierten S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion

  2021cites this paper
• In Vitro Infection with Hepatitis B Virus Using Differentiated Human Serum Culture of Huh7.5-NTCP Cells without Requiring Dimethyl Sulfoxide

  2021cites this paper
• Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B.

  2021cites this paper
• Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update.

  2021cites this paper
• Breakthroughs and challenges in the management of pediatric viral hepatitis

  2021cites this paper
• Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a

  2020influential citation
• Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020).

  2020cites this paper
• Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B

  2020cites this paper
• Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: A systematic review and meta-analysis.

  2020cites this paper
• Dynamics of HBV Surface Antigen Related end Points in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis

  2020cites this paper
• Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020)

  2020cites this paper
• Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a

  2020cites this paper
• The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk.

  2020cites this paper
• Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

  2020cites this paper
• Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

  2019cites this paper
• Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study

  2019cites this paper
• A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a

  2019cites this paper
• Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis

  2019cites this paper
• Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B

  2019cites this paper
• Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data

  2019cites this paper
• BARRIERS TO THE PREVENTION AND CONTROL OF THE HEPATITIS B IN THE COMMUNITY

  2019cites this paper
• A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals

  2019cites this paper
• Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B

  2019cites this paper
• KASL clinical practice guidelines for management of chronic hepatitis B

  2019cites this paper
• Taiwan consensus statement on the management of chronic hepatitis B.

  2019cites this paper
• The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients

  2019cites this paper
• Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection

  2019cites this paper
• Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B

  2018cites this paper
• A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B

  2018cites this paper
• Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence

  2018cites this paper
• Hepatitis B virus infection

  2018cites this paper
• Extended duration of treatment with peginterferon alfa‐2a in patients with chronic hepatitis B, HBeAg‐negative and E genotype: A retrospective analysis

  2018cites this paper
• An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings

  2018cites this paper
• EFFICACY AND SAFETY OF PEGYLATED-INTERFERON ALPHA THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B IN RECOURCE- LIMITED SETTINGS- SERBIAN SINGLE-CENTER EXPERIENCE EFIKASNOST I SIGURNOST PEGILOVANOG INTERFERONA ALFA- 2A U TERAPIJI HRONIČNOG B VIRUSNOG HEPATITISA- NAŠA ISKUSTVA Authors

  2018cites this paper
• Hepatitis B

  2018cites this paper
• Hepatitis B Treatment: What We Know Now and What Remains to Be Researched

  2018cites this paper
• Consensus Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B

  2018cites this paper
• Effect of Pegylated Interferon Add-On Therapy to Achieve Disease Remission in Patients with Chronic Hepatitis B

  2018cites this paper
• HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study

  2018influential citation
• Add‐on peginterferon alfa‐2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen‐negative chronic hepatitis B genotype D

  2018cites this paper
• The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment.

  2017cites this paper
• Guidelines on the management of hepatitis B virus infection q European Association for the Study of the Liver

  2017cites this paper
• EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2017cites this paper
• Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-

  2017cites this paper
• Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

  2017cites this paper
• Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features

  2017cites this paper
• Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives

  2017cites this paper
• Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment

  2017cites this paper
• Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs

  2017cites this paper
• Hepatocellular carcinoma – a new possibility to individalise theray among patients with advenced diseases

  2017cites this paper
• Response to Pegylated Interferon in Hepatitis B patients with HBe Ag-Negative: Long-Term Results and Predictors of Sustained-Off VIirological Response

  2017cites this paper
• Metabonomic window into hepatitis B virus-related hepatic diseases.

  2016cites this paper
• Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study.

  2016cites this paper
• IFN-Based Therapy and Management of Patients

  2016cites this paper
• Pharmacotherapeutic options for hepatitis B

  2016cites this paper
• Virus-host interplay in chronic hepatitis B: Predicting response to immunomodulating antiviral therapy

  2016cites this paper
• Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion

  2016cites this paper
• Pegylated interferon alfa for chronic hepatitis B: systematic review and meta‐analysis

  2016cites this paper
• Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection

  2016cites this paper
• Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis.

  2016cites this paper
• Interferon Treatment for Hepatitis B.

  2016cites this paper
• A randomized clinical trial of peginterferon alpha‐2b with or without entecavir in patients with HBeAg‐negative chronic hepatitis B: Role of host and viral factors associated with treatment response

  2016cites this paper
• Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a.

  2016cites this paper
• A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.

  2015cites this paper
• Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

  2015cites this paper
• Chronic hepatitis B therapy: available drugs and treatment guidelines.

  2015cites this paper
• Improved Efficacy of a Pegylated Interferon-α-2a Stepwise Optimization Treatment Strategy in the Treatment of Hepatitis B e Antigen-positive Chronic Hepatitis B Patients

  2015cites this paper
• Clinical correlation between HBV infection and concomitant bacterial infections

  2015cites this paper
• Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon

  2015cites this paper
• Management of chronic hepatitis B infection

  2015cites this paper
• Current and future directions for treating hepatitis B virus infection.

  2015cites this paper
• Optimal therapy of chronic hepatitis B: how do I treat my HBeAg‐negative patients?

  2015cites this paper
• THE NEED FOR HBV GENOTYPING: A COST-EFFICIENT APPROACH.

  2015cites this paper
• A response-guided approach based on HBsAg kinetics may identify patients with the greatest chance of success.

  2015cites this paper
• Hepatitis B: encouraging the use of interferon

  2015cites this paper
• Monotherapy for hepatitis B infection: a review of treatment options

  2015cites this paper
• A Review on Therapeutic Management of Chronic Hepatitis B Infection

  2015cites this paper
• The 2014 Hepatology Society of the Philippines Consensus Statements on the Management of Chronic Hepatitis B

  2015cites this paper
• The decrease of HBsAg during nucleos(t)ide analogues (NUC) therapy in Bulgarian patients

  2015cites this paper
• Improving clinical outcomes of chronic hepatitis B virus infection

  2015cites this paper
• NEURO-MENTAL DISORDERS IN CHRONIC PARENTERAL HEPATITIS’ PATIENTS

  2015cites this paper
• Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection

  2014cites this paper
• Pegylated Interferon Alfa 2a Treatment in Patients with Chronic Hepatitis B and Genotype D in Jordan

  2014cites this paper
• Systematic review with meta‐analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon‐therapy in hepatitis B infection?

  2014cites this paper
• Chronic hepatitis B: Advances in treatment.

  2014cites this paper
• Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.

  2014cites this paper
• HBeAg‐negative chronic hepatitis B: why do I treat my patients with pegylated interferon‐alfa?

  2014cites this paper